Stem cell-based therapy (SCM Lifescience/Steminent Biotherapeutics)(Stem cell-based therapy (SCM Lifescience/Steminent Biotherapeutics)) - 在研适应症：慢性移植物抗宿主病，特应性皮炎，胰腺炎_专利_临床

概要

基本信息

药物类型

干细胞疗法

别名-

靶点-

作用机制

细胞替代物

治疗领域

免疫系统疾病遗传病与畸形消化系统疾病+ [2]

在研适应症

慢性移植物抗宿主病特应性皮炎胰腺炎

非在研适应症

小脑共济失调成人呼吸窘迫综合征

原研机构

SCM Lifescience Co., Ltd.

在研机构

SCM Lifescience Co., Ltd.

非在研机构

仲恩生医科技股份有限公司

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Stem cell-based therapy (SCM Lifescience/Steminent Biotherapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Stem cell-based therapy (SCM Lifescience/Steminent Biotherapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Stem cell-based therapy (SCM Lifescience/Steminent Biotherapeutics) 相关的专利（医药）

登录后查看更多信息

1

项与 Stem cell-based therapy (SCM Lifescience/Steminent Biotherapeutics) 相关的文献（医药）

2011-02-01·Medical Hypotheses4区 · 医学

Mesenchymal stem cell-based cellular vaccine: An efficient immunotherapeutic strategy for human malignancies

4区 · 医学

Article

作者: Xiancheng Chen ; Jiangdong Xiang ; Lina Zhou

Cancer-related deaths are still the most fearsome threaten to human health. It is necessary to develop an innovative and active strategy for the prophylactic immunization against tumorigenesis. Multiple lines of evidence have demonstrated that cancer stem cells (CSCs) are the initiating cells of tumor formation, as well as the source of local recurrence and distant metastases. Mesenchymal stem cells (MSCs), the adult pluripotent progenitors of multiple mesenchymal lineages, have an unusual tropism to preclinical tumor lesions. Both MSCs and CSCs or populations of tumor-initiating cells may also have similar reactogenicity or immunogenicity. Based on the information given above, a hypothesis is generated that MSCs may possess a potential of cellular vaccine for bio-prevention against tumorigenesis via eliciting cross-immunity and inducing active antibodies.

100 项与 Stem cell-based therapy (SCM Lifescience/Steminent Biotherapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性移植物抗宿主病	临床2期	韩国	SCM Lifescience Co., Ltd.	2022-01-30
特应性皮炎	临床2期	韩国	SCM Lifescience Co., Ltd.	2022-01-30
胰腺炎	临床2期	韩国	SCM Lifescience Co., Ltd.	2022-01-30
成人呼吸窘迫综合征	临床1期	韩国	SCM Lifescience Co., Ltd.	2021-11-16
小脑共济失调	临床1期	韩国	仲恩生医科技股份有限公司	2020-03-14